GRTX.OQBGalera Therapeutics, INC
10-K: Galera Therapeutics Faces Setbacks, Explores Strategic Alternatives Amid Clinical Trial Halts and FDA Rejection
Sentiment:
Annual Report
Galera Therapeutics halts clinical trials and explores strategic alternatives following an FDA rejection and disappointing trial results.
Delay expectedThe CRL received from the FDA for avasopasem indicates a delay in the regulatory approval process, as it necessitates an additional clinical trial.The halting of the rucosopasem trials represents a delay in the development timeline for that product candidate.
Capital raiseIn February 2023, the Company completed a registered direct offering, which resulted in the issuance and sale of 14,320,000 shares of its common stock and warrants to purchase up to 14,320,000 shares of common stock at a combined offering price of $2.095 per share and accompanying warrant, generating gross proceeds of $30.0 million.The warrants have an exercise price of $1.97 per share of common stock, are exercisable immediately following their issuance and will expire five years from the date of issuance.The Company received net proceeds of approximately $27.6 million from this offering, after deducting placement agent fees and offering expenses.
Worse than expectedThe receipt of a Complete Response Letter (CRL) from the FDA for avasopasem indicates that the clinical data did not meet the necessary thresholds for approval, which is a worse than expected outcome.The halting of the Phase 2b GRECO-2 and Phase 1/2 GRECO-1 trials for rucosopasem following a futility analysis suggests that the drug was not performing as expected in clinical development.The need for an additional Phase 3 trial for avasopasem, coupled with the company's inability to conduct it due to resource constraints, represents a significant setback compared to the expected progress in the drug development process.
Summary
- Galera Therapeutics, a biopharmaceutical company, has focused on developing therapeutics for cancer radiotherapy.
- Its lead product candidate, avasopasem, received Fast Track and Breakthrough Therapy designations from the FDA for reducing severe oral mucositis (SOM) in head and neck cancer (HNC) patients.
- In August 2023, Galera received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for avasopasem, indicating the need for an additional clinical trial.
- Due to resource constraints, Galera is unable to conduct the additional trial and is exploring alternative development paths for avasopasem.
- The company initiated a workforce reduction of approximately 70% and wound down commercial readiness efforts for avasopasem.
- In October 2023, Galera halted Phase 2b and Phase 1/2 trials of its second product candidate, rucosopasem, due to futility analysis.
- The company has engaged a financial advisor to explore strategic alternatives, including a merger, sale, divestiture of assets, or licensing.
- Galera reported net losses of $59.1 million in 2023 and $62.2 million in 2022, with an accumulated deficit of $437.4 million as of December 31, 2023.
- Existing cash and cash equivalents are projected to fund operations into the second quarter of 2025.
- The company is facing delisting from The Nasdaq Global Market due to non-compliance with listing requirements and has requested a hearing to appeal the delisting determinations.
Sentiment
Score: 2
Explanation: The low score is due to the negative developments including the FDA's rejection, clinical trial halts, workforce reduction, and the company's precarious financial position.
Positives
- Avasopasem has received Fast Track and Breakthrough Therapy designations from the FDA.
- Rucosopasem has received orphan drug designation from the FDA and EMA for the treatment of pancreatic cancer.
- The company is actively exploring strategic alternatives to maximize stockholder value.
Negatives
- Receipt of a Complete Response Letter (CRL) from the FDA for avasopasem, indicating the need for an additional clinical trial.
- Inability to conduct the additional trial due to resource constraints.
- Halting of Phase 2b and Phase 1/2 trials of rucosopasem.
- Significant workforce reduction of approximately 70%.
- Substantial net losses and accumulated deficit.
- Potential delisting from Nasdaq due to non-compliance with listing requirements.
Risks
- The company may be unable to undertake any suitable strategic alternative, potentially leading to the cessation of operations.
- The company may never succeed in developing and commercializing product candidates that generate significant revenue.
- Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishment of rights to technologies or product candidates.
- Clinical trials may fail to demonstrate safety and efficacy, leading to the inability to obtain regulatory approvals.
- The company faces substantial competition in the development of novel cancer therapies.
- The company's intellectual property may be challenged, invalidated, or infringed upon, impacting its ability to commercialize products.
- The company is subject to extensive healthcare regulations, and non-compliance could result in penalties.
- Unfavorable global economic conditions could adversely affect the company's business and financial condition.
- The company's stock price is likely to be volatile and may fluctuate substantially.
- If the company's common stock is delisted from Nasdaq, it could make trading more difficult for investors and negatively impact the stock's liquidity and price.
Future Outlook
The company's future success is dependent on identifying and consummating a strategic transaction, and if unsuccessful, the board may decide to pursue a dissolution and liquidation of the company.
Industry Context
Galera Therapeutics operates in the biopharmaceutical industry, focusing on developing cancer therapeutics, particularly those that can enhance radiotherapy. The industry is characterized by high competition, extensive regulation, and the need for substantial investment in research and development. The company's focus on addressing side effects of cancer treatments like radiotherapy-induced toxicities places it in a niche with significant unmet medical needs.
Comparison to Industry Standards
- Compared to industry standards, Galera's receipt of a CRL and subsequent halting of clinical trials are significant setbacks. Many biopharmaceutical companies face challenges in clinical development, but the need for an additional Phase 3 trial as indicated by the FDA suggests that avasopasem's clinical data did not meet the expected efficacy or safety thresholds typically required for approval.
- For example, companies like Bristol Myers Squibb and Merck have successfully brought oncology drugs to market, demonstrating the ability to navigate the regulatory landscape and meet FDA requirements.
- Galera's financial position, with substantial losses and reliance on future funding, is not uncommon for development-stage biotech companies. However, the lack of revenue and the need to explore strategic alternatives highlight the company's precarious position compared to more established peers.
- In the specific area of radioprotection, there are currently no FDA-approved drugs for the treatment of OM in patients with HNC. This highlights a significant unmet need in the market, but also underscores the difficulty in developing effective treatments in this area. Companies like Amgen have previously attempted to address this market with products like Kepivance (palifermin), which is approved for reducing severe oral mucositis in patients undergoing chemotherapy and radiation for hematologic malignancies, but not specifically for HNC related to radiotherapy. Galera's efforts, while facing setbacks, represent an attempt to address a gap in the current treatment landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Bylaw Amendment | Amended and restated bylaws to enhance procedural mechanics for stockholder nominations and proposals, address Universal Proxy Rules, clarify meeting procedures, and make other updates. | March 27, 2024 | These changes aim to improve corporate governance practices and align with regulatory requirements, potentially affecting stockholder interactions and meeting procedures. |
Legal Proceedings
- On May 30, 2023, the Company filed a lawsuit against Alira Health Clinical, LLC and IQVIA Biotech, LLC, alleging breach of contract, professional negligence, and negligence related to an error in the statistical program for the Phase 3 ROMAN trial of avasopasem.
- In October 2023, the Court granted a joint motion to stay the lawsuit, and in March 2024 the Court granted a joint motion to continue the stay until April 22, 2024.
Related Party Transactions
- IntellectMap provides IT-advisory services to the Company. The chief executive officer of IntellectMap is the brother of the Companys chief executive officer. Fees incurred by the Company with respect to IntellectMap during the years ended December 31, 2023 and 2022 were $0.3 million and $0.2 million, respectively.
Stakeholder Impact
- Shareholders: Potential negative impact due to the uncertainty surrounding the company's future, the risk of delisting, and the possibility of dilution from future capital raises.
- Employees: Approximately 70% workforce reduction has significant implications for job security and morale among remaining employees.
- Customers: The company does not have marketed products, so there is no direct impact on customers.
- Suppliers: The reduction in operations may lead to decreased demand for goods and services from suppliers.
- Creditors: The company's ability to meet its obligations may be impacted by its financial position and the outcome of strategic alternatives.
Next Steps
- Explore and evaluate strategic alternatives, which may include a merger, sale, divestiture of assets, licensing, or other strategic transactions.
- Continue to explore appropriate development paths for avasopasem.
- Engage with the FDA to discuss potential resubmission of the NDA for avasopasem.
- Address Nasdaq's delisting notices and participate in the hearing process to appeal the determinations.
Key Dates
| Date | Description |
|---|---|
| 2020-05-31 | Date of Amended Royalty Agreements |
| 2018-11-01 | First Tranche of Royalty Purchase Price received |
| 2019-04-01 | Second tranche of Royalty Purchase Price received |
| 2019-11-01 | Start date for Two Thousand Nineteen Incentive Award Plan |
| 2019-11-03 | Start date for Two Thousand Nineteen Employee Stock Purchase Plan |
| 2019-11-07 | Galera Therapeutics common stock begins trading on the Nasdaq Global Market |
| 2020-02-01 | Third tranche of Royalty Purchase Price received |
| 2020-05-31 | Date of Amended Royalty Agreements |
| 2020-12-01 | Start date for ATM Offering |
| 2020-12-31 | End date for ATM Offering |
| 2021-07-31 | Fourth Tranche of Royalty Purchase Price received |
| 2021-06-01 | New $20.0 million tranche of the Amendment received in connection with the enrollment of the first patient in the GRECO-2 trial |
| 2021-07-01 | $37.5 million received in connection with the completed enrollment in the ROMAN trial |
| 2022-01-01 | Start date for IntellectMap |
| 2022-12-31 | End date for IntellectMap |
| 2023-01-01 | Start date for Stock Options |
| 2023-02-17 | Date of registered direct offering, resulting in the issuance and sale of 14,320,000 shares of common stock and warrants |
| 2023-04-28 | Date of adoption of the 2023 Employment Inducement Award Plan |
| 2023-08-09 | Announcement of receipt of a Complete Response Letter (CRL) from the FDA regarding the New Drug Application (NDA) for avasopasem and workforce reduction |
| 2023-09-22 | Receipt of written notices from The Nasdaq Stock Market LLC indicating non-compliance with the minimum Market Value of Listed Securities and the Minimum Bid Price Requirement |
| 2023-09-25 | Receipt of an additional written notice from Nasdaq indicating non-compliance with the minimum Market Value of Publicly Held Shares |
| 2023-10-01 | Halting of Phase 2b GRECO-2 and Phase 1/2 GRECO-1 trials of rucosopasem |
| 2023-12-31 | End of fiscal year |
| 2024-01-01 | Start date for Two Thousand Nineteen Incentive Award Plan |
| 2024-03-20 | Deadline to regain compliance with the MVLS Requirement and the Minimum Bid Price Requirement |
| 2024-03-21 | Receipt of a notice of delisting from Nasdaq for not regaining compliance with the Minimum Bid Price Requirement or the MVLS Requirement |
| 2024-03-25 | Deadline to regain compliance with the MVPHS Requirement |
| 2024-03-26 | Receipt of a notice of delisting from Nasdaq for not regaining compliance with the MVPHS requirement |
| 2024-03-26 | Number of shares of registrants Common Stock outstanding |
| 2024-03-28 | Request for a hearing before a Nasdaq Hearings Panel to appeal Nasdaqs delisting determinations |
Keywords
Galera Therapeutics, avasopasem, rucosopasem, radiotherapy, cancer, severe oral mucositis, head and neck cancer, esophagitis, lung cancer, FDA, clinical trials, strategic alternatives, merger, acquisition, licensing, biopharmaceutical, Nasdaq, delisting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.